BioCardia CEO reports RSU tax withholding, option grant

BioCardia, Inc. President and CEO Peter Altman reported routine equity compensation activity.

Rhea-AI Filing Summary

BioCardia, Inc. President and CEO Peter Altman reported routine equity compensation activity. On July 2, 2026, 54,606 shares of common stock were withheld by the company at $1.24 per share to cover income tax obligations on vested RSUs, and this did not represent a market sale by Altman. Following this tax-withholding disposition, he directly held 356,585 common shares. On July 6, 2026, he received a grant of stock options for 57,688 shares of common stock at a $1.20 exercise price, expiring on July 6, 2036, with vesting in 1/48th monthly installments beginning August 6, 2026, contingent on continued service, resulting in 147,903 options held after the grant.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Altman Peter

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	57,688	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	54,606	$1.24	$68K

Holdings After Transaction: Stock Option (right to buy) — 147,903 contracts (Direct); Common Stock — 356,585 shares (Direct)

Footnotes (2)

1. F1. The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person.
2. F2. The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.

Key Figures

RSU tax-withholding shares: 54,606 shares Withholding reference price: $1.24 per share Post-transaction common shares: 356,585 shares +4 more

7 metrics

RSU tax-withholding shares 54,606 shares Common stock withheld on July 2, 2026 to satisfy tax obligations

Withholding reference price $1.24 per share Price used for 54,606 common shares withheld for tax obligations

Post-transaction common shares 356,585 shares Common stock directly held after July 2, 2026 tax-withholding disposition

New option grant size 57,688 options Stock options granted on July 6, 2026 over common stock

Option exercise price $1.20 per share Exercise price for 57,688 newly granted stock options

Option expiration date July 6, 2036 Expiration for newly granted stock options

Post-grant options held 147,903 options Total stock options held following the July 6, 2026 grant

Key Terms

RSUs, net settlement, stock option, income tax, withholding and remittance obligations, +1 more

5 terms

RSUs financial

"the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

net settlement financial

"in connection with the net settlement on July 2, 2026, of the RSUs vested"

stock option financial

"The option vests and becomes exercisable as to 1/48th of the shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

income tax, withholding and remittance obligations financial

"withheld by the Issuer to satisfy its income tax, withholding and remittance obligations"

vests and becomes exercisable financial

"The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BioCardia (BCDA) report for Peter Altman?

BioCardia reported that CEO Peter Altman had 54,606 shares withheld to cover tax obligations on vested RSUs and received a grant of 57,688 stock options at a $1.20 exercise price, expiring in 2036, as part of his equity compensation.

Did BioCardia CEO Peter Altman sell BCDA shares in this Form 4 filing?

No, the filing states the 54,606 shares were withheld by BioCardia to satisfy income tax and withholding obligations on vested RSUs. The footnote clarifies this was a tax-withholding disposition by the issuer and does not represent an open-market sale by Altman.

What are the terms of Peter Altman’s new BioCardia stock option grant?

Peter Altman was granted options for 57,688 shares of BioCardia common stock at a $1.20 exercise price, expiring July 6, 2036. The options vest monthly in 1/48th increments starting August 6, 2026, subject to his continued service with the company.

How many BioCardia shares does Peter Altman hold after the reported transactions?

After the tax-withholding transaction, Peter Altman directly holds 356,585 shares of BioCardia common stock. The filing also shows he holds 147,903 stock options following the new grant, providing additional potential future equity exposure if those options are exercised.

Why were 54,606 BioCardia shares withheld in Peter Altman’s Form 4?

The 54,606 shares were withheld by BioCardia to meet income tax, withholding, and remittance obligations from the net settlement of RSUs that vested on June 29, 2026. This mechanism settles taxes without requiring Altman to sell shares in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 10:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		F		54,606(1)	D	$1.24(1)	356,585	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.2	07/06/2026		A		57,688		(2)	07/06/2036	Common stock	57,688	$0	147,903	D

Explanation of Responses:

1. The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person.

2. The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.

	/s/ David McClung, by power of attorney	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)